|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/24/15 Shire plc 10-K 12/31/14 134:21M Davis Polk & … LLP 01/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.79M
2: EX-21 Subsidiaries List HTML 74K
3: EX-23.1 Consent of Experts or Counsel HTML 36K
4: EX-23.2 Consent of Experts or Counsel HTML 37K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 43K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 43K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 37K
88: R1 Document and Entity Information HTML 65K
66: R2 Consolidated Balance Sheets HTML 149K
83: R3 Consolidated Balance Sheets (Parenthetical) HTML 49K
92: R4 Consolidated Statements of Income HTML 167K
121: R5 Consolidated Statements of Income (Parenthetical) HTML 48K
70: R6 Consolidated Statements of Comprehensive Income HTML 75K
82: R7 Consolidated Statements of Comprehensive Income HTML 38K
(Parenthetical)
59: R8 Consolidated Statements of Changes in Equity HTML 130K
47: R9 Consolidated Statements of Changes in Equity HTML 51K
(Parenthetical)
123: R10 Consolidated Statements of Cash Flows HTML 229K
94: R11 Shire Income Access Share Trust Balance Sheet HTML 57K
93: R12 Shire Income Access Share Trust Statement of HTML 44K
Income
101: R13 Shire Income Access Share Trust Statements of HTML 61K
Changes in Equity
102: R14 Shire Income Access Share Trust Statements of HTML 80K
Cashflows
98: R15 Description of Operations HTML 38K
103: R16 Summary of Significant Accounting Policies HTML 130K
84: R17 Business Combinations HTML 147K
89: R18 Divestment of Product Rights HTML 41K
96: R19 Reorganization Costs HTML 54K
133: R20 Integration and acquisition costs HTML 40K
112: R21 Accounts Receivable, Net HTML 48K
76: R22 Inventories HTML 42K
95: R23 Results of discontinued operations HTML 51K
79: R24 Prepaid Expenses and Other Current Assets HTML 41K
36: R25 Property, Plant and Equipment, Net HTML 46K
114: R26 Goodwill HTML 48K
128: R27 Other Intangible Assets, Net HTML 61K
53: R28 Accounts Payable and Accrued Expenses HTML 45K
52: R29 Other Current Liabilities HTML 41K
57: R30 Borrowings HTML 61K
58: R31 Other Non-current Liabilities HTML 42K
60: R32 Commitments and Contingencies HTML 102K
24: R33 Accumulated Other Comprehensive Income HTML 51K
110: R34 Financial Instruments HTML 69K
74: R35 Fair Value Measurement HTML 117K
77: R36 Shareholders' Equity HTML 70K
41: R37 Earnings Per Share HTML 77K
132: R38 Segmental Reporting HTML 88K
14: R39 Receipt of Break Fee HTML 41K
63: R40 Retirement Benefits HTML 40K
119: R41 Taxation HTML 145K
38: R42 Related Parties HTML 44K
51: R43 Share-based Compensation Plans HTML 128K
56: R44 Quarterly Results of Operations (Unaudited) HTML 72K
67: R45 Notes to the Shire Income Access Share Trust HTML 46K
Financial Statements
23: R46 Schedule II - Valuation and Qualifying Accounts HTML 57K
46: R47 Summary of Significant Accounting Policies HTML 219K
(Policies)
17: R48 Business Combinations (Tables) HTML 70K
117: R49 Reorganization costs (Table) HTML 46K
37: R50 Accounts Receivable, Net (Tables) HTML 41K
111: R51 Inventories (Tables) HTML 41K
42: R52 Results of discontinued operations (Table) HTML 45K
64: R53 Prepaid Expenses and Other Current Assets (Tables) HTML 41K
16: R54 Property, Plant and Equipment, Net (Tables) HTML 43K
20: R55 Goodwill (Tables) HTML 46K
55: R56 Other Intangible Assets, Net (Tables) HTML 54K
28: R57 Accounts Payable and Accrued Expenses (Tables) HTML 44K
124: R58 Other Current Liabilities (Tables) HTML 40K
72: R59 Other Non-current Liabilities (Tables) HTML 41K
99: R60 Commitments and Contingencies (Tables) HTML 42K
45: R61 Accumulated Other Comprehensive Income (Tables) HTML 46K
49: R62 Financial Instruments (Tables) HTML 50K
108: R63 Fair Value Measurement (Tables) HTML 108K
104: R64 Earnings Per Share (Tables) HTML 77K
75: R65 Segmental Reporting (Tables) HTML 85K
106: R66 Taxation (Tables) HTML 128K
43: R67 Share-based Compensation Plans (Tables) HTML 99K
80: R68 Quarterly Results of Operations (Tables) HTML 69K
127: R69 Summary of Significant Accounting Policies HTML 71K
(Details)
19: R70 Business Combinations (ViroPharrma,NPS Pharma, HTML 235K
Meritage) (Details)
35: R71 Business Combinations (Pro Forma Information) HTML 65K
(Details)
65: R72 Business Combinations (Lumena, Fibrotech and Other HTML 209K
Acquisitions) (Details)
26: R73 Divestment of Product Rights (Details) HTML 47K
131: R74 Reorganization Costs (Details) HTML 67K
39: R75 Integration and acquisition costs (Details) HTML 43K
30: R76 Accounts Receivable, Net (Details) HTML 52K
34: R77 Inventories (Details) HTML 48K
21: R78 Results of discontinued operations (Details) HTML 98K
25: R79 Prepaid Expenses and Other Current Assets HTML 50K
(Details)
90: R80 Property Plant and Equipment (Details) HTML 59K
32: R81 Goodwill (Details) HTML 56K
125: R82 Other Intangible Assets, Net (Details) HTML 92K
61: R83 Other Intangible Assets, Net (Roll Forward) HTML 63K
(Details)
97: R84 Accounts Payable and Accrued Expenses (Details) HTML 66K
105: R85 Other Current Liabilities (Details) HTML 51K
31: R86 Borrowings (Details) HTML 134K
33: R87 Other Non-current Liabilities (Details) HTML 52K
122: R88 Commitments and Contingencies (Leases, and LC and HTML 65K
Guarantees ) (Details)
27: R89 Commitments and Contingencies (Collaborative HTML 77K
Arrangements) (Details)
91: R90 Commitments and Contingencies (Commitments and HTML 66K
Loss Contingency) (Details)
87: R91 Accumulated Other Comprehensive Income (Details) HTML 66K
109: R92 Financial Instruments (Interest Rate and Credit HTML 82K
Risks) (Details)
86: R93 Financial Instruments (Foreign Exchange Risk and HTML 63K
Its Classification on Balance Sheet) (Details)
71: R94 Financial Instruments (Foreign Exchange Risk and HTML 39K
Its Effect on Income Statement) (Details)
116: R95 Fair Value Measurement (Assets and Liabilities HTML 94K
That are Measured and Not Measured at Fair Value
on a Recurring Basis) (Details)
68: R96 Fair Value Measurement (Assets and Liabilities HTML 89K
Measured at Fair Value on a Recurring Basis Using
Significant Unobservable Inputs) (Details)
40: R97 Fair Value Measurement (Quantitative Information HTML 106K
About Recurring and Non-recurring Level 3 Fair
Value Measurements) (Details)
78: R98 Shareholders' Equity (Details) HTML 112K
73: R99 Earnings Per Share (Details) HTML 159K
54: R100 Segmental Reporting (Revenues and Long-lived HTML 68K
Assets by Geographic Location) (Details)
134: R101 Segmental Reporting (Revenues and Accounts HTML 67K
Receivable by Major Customers) (Details)
107: R102 Segmental Reporting (Revenue by Product) (Details) HTML 78K
85: R103 Receipt of Break Fee (Details) HTML 41K
22: R104 Retirement Benefits (Details) HTML 37K
118: R105 Taxation (Pretax Income from Continuing Operations HTML 106K
and Provision for Income Taxes) (Details)
126: R106 Taxation (Effective Income Tax Rate HTML 152K
Reconciliation, and Statutory Tax Rates) (Details)
120: R107 Taxation (Unrecognized Tax Benefits) (Details) HTML 89K
81: R108 Taxation (Deferred Tax Assets and Liabilities, and HTML 126K
Valuation Allowances) (Details)
29: R109 Taxation (Operating Loss and Tax Credit HTML 80K
Carryforwards, and Their Expiration Dates)
(Details)
100: R110 Related parties (Details) HTML 47K
44: R111 Share-based Compensation Plans (Share-based HTML 74K
Compensation Expense) (Details)
15: R112 Share-based Compensation Plans (by Share-based HTML 79K
Payment Award) (Details)
69: R113 Share-based Compensation Plans (Stock Options and HTML 129K
SARs) (Details)
62: R114 Share-based Compensation Plans (Performance Share HTML 80K
Awards) (Details)
113: R115 Share-based Compensation Plans (Fair Value HTML 69K
Assumptions) (Details)
48: R116 Quarterly Results of Operations (Details) HTML 107K
130: R117 Schedule II - Valuation and Qualifying Accounts HTML 76K
(Details)
129: XML IDEA XML File -- Filing Summary XML 218K
18: EXCEL IDEA Workbook of Financial Reports XLSX 310K
50: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 2.23M
8: EX-101.INS XBRL Instance -- shpgf-20140930 XML 3.82M
10: EX-101.CAL XBRL Calculations -- shpgf-20140930_cal XML 381K
11: EX-101.DEF XBRL Definitions -- shpgf-20140930_def XML 1.99M
12: EX-101.LAB XBRL Labels -- shpgf-20140930_lab XML 3.71M
13: EX-101.PRE XBRL Presentations -- shpgf-20140930_pre XML 2.75M
9: EX-101.SCH XBRL Schema -- shpgf-20140930 XSD 401K
115: ZIP XBRL Zipped Folder -- 0000950103-15-001422-xbrl Zip 397K
|
Subsidiary/undertaking
|
Jurisdiction of incorporation
|
|
Advanced BioHealing Corp
|
United States
|
|
Auralis Limited
|
United Kingdom
|
|
Bikam Pharmaceuticals, Inc.
|
United States
|
|
DuoCort Pharma AB
|
Sweden
|
|
Farboud Pty Ltd
|
Australia
|
|
FerroKin BioSciences, Inc.
|
United States
|
|
Fibrotech Therapeutics Pty Ltd
|
Australia
|
|
Jerini Ophthalmic Holding GmbH
|
Germany
|
|
Jerini Ophthalmic, Inc
|
United States
|
|
JPT Peptide Technologies Inc
|
United States
|
|
Lotus Tissue Repair Inc
|
United States
|
|
Lumena Pharma UK Limited
|
United Kingdom
|
|
Lumena Pharmaceuticals LLC
|
United States
|
|
Monmouth Pharmaceuticals Limited
|
United Kingdom
|
|
Movetis GmbH
|
Germany
|
|
Movetis Limited
|
United Kingdom
|
|
Pharma International Insurance Limited
|
Ireland
|
|
Premacure AB
|
Sweden and Luxembourg
|
|
Premacure Uppsala AB
|
Sweden
|
|
Rybar Laboratories Limited
|
United Kingdom
|
|
SARcode Bioscience Inc.
|
United States
|
|
SHGT Executive Services Inc.
|
United States
|
|
Shire (Shanghai) Pharmaceuticals Consultancy Co., Ltd.
|
China
|
|
Shire 2005 Investments Limited
|
Cayman Islands
|
|
Shire Acquisitions UK Limited
|
United Kingdom
|
|
Shire Australia Pty Limited
|
Australia
|
|
Shire Belgium BVBA
|
Belgium
|
|
Shire Biopharmaceuticals Holdings
|
United Kingdom
|
|
Shire Biopharmaceuticals Holdings Ireland Limited
|
Jersey
|
|
Shire Biopharmaceuticals Ireland Limited
|
Ireland
|
|
Shire Brandywine LLC
|
United States
|
|
Shire Pharma Canada ULC
|
Canada
|
|
Shire Central & Eastern Europe GmbH
|
Germany
|
|
Shire Colombia S.A.S
|
Colombia
|
|
Shire Czech S.R.O.
|
Czech Republic
|
|
Shire Denmark ApS
|
Denmark
|
|
Shire Deutschland GmbH
|
Germany
|
|
Shire Deutschland Investments GmbH
|
Germany
|
|
Shire Development LLC
|
United States
|
|
Shire Europe Finance
|
United Kingdom
|
|
Shire Europe Limited
|
United Kingdom
|
|
Shire Executive Services LLC
|
United States
|
|
Shire Farmacêutica Brasil LTDA
|
Brazil
|
|
Shire Finance Limited
|
Cayman Islands
|
|
Shire Finland Oy
|
Finland
|
|
Shire France S.A.
|
France
|
|
Shire Global Finance
|
United Kingdom
|
|
Shire Hellas Pharmaceuticals Import Export and Marketing S.A.
|
Greece
|
|
Shire Holdings Europe B.V.
|
Netherlands
|
|
Shire Holdings Europe Limited
|
United Kingdom
|
|
Shire Holdings Europe No.2 S.a.r.l.
|
Luxembourg
|
|
Shire Holdings Ireland
|
Ireland
|
|
Shire Holdings Ireland No.2 Limited
|
Ireland
|
|
Shire Holdings Limited
|
Bermuda
|
|
Shire Holdings Luxembourg S.a r.l.
|
Luxembourg
|
|
Shire Holdings UK Canada Limited
|
United Kingdom
|
|
Shire Holdings UK Limited
|
United Kingdom
|
|
Shire Holdings US AG
|
United States
|
|
Shire Human Genetic Therapies (Canada) Inc.
|
Canada
|
|
Shire Human Genetic Therapies AB
|
Sweden
|
|
Shire Human Genetic Therapies Limited
|
United Kingdom
|
|
Shire Human Genetic Therapies S.A.
|
Argentina
|
|
Shire Human Genetic Therapies Securities Corporation
|
United States
|
|
Shire Human Genetic Therapies UK Limited
|
United Kingdom
|
|
Shire Human Genetic Therapies, Inc
|
United States
|
|
SHIRE ILAC TICARET LIMITED SIRKETI / Shire Pharmaceuticals Trading Limited Company
|
Turkey
|
|
Shire Incorporated
|
United States
|
|
Shire Intellectual Property 2 SRL
|
Barbados
|
|
Shire Intellectual Property Ireland Limited
|
Ireland
|
|
Shire Intellectual Property SRL
|
Barbados
|
|
Shire International GmbH
|
Switzerland
|
|
Shire International Licensing BV
|
Netherlands
|
|
Shire International Licensing VOF
|
Netherlands
|
|
Shire Investments & Finance (U.K.) Company
|
United Kingdom
|
|
Shire IP Services Corporation
|
Canada
|
|
Shire Ireland Finance Limited
|
Ireland
|
|
Shire Ireland Investment Limited
|
Ireland
|
|
Shire Ireland Premacure Investment
|
Ireland
|
|
Shire Italia S.p.A.
|
Italy
|
|
Shire Japan KK
|
Japan
|
|
Shire Jersey Limited
|
Jersey
|
|
Shire LLC
|
United States
|
|
Shire Luxembourg Finance S.a.r.l.
|
Luxembourg
|
|
Shire Luxembourg Intellectual Property No.2 S.a r.l.
|
Luxembourg
|
|
Shire Luxembourg Intellectual Property No.3 S.a.r.l.
|
Luxembourg
|
|
Shire Luxembourg Intellectual Property S.a r.l.
|
Luxembourg
|
|
Shire Luxembourg Sarl
|
Luxembourg
|
|
Shire North American Group Inc.
|
United States
|
|
Shire Norway AS
|
Norway
|
|
Shire Orphan and Rare Diseases GmbH
|
Switzerland
|
|
Shire Orphan Therapies GmbH
|
Germany
|
|
Shire Orphan Therapies, Inc.
|
United States
|
|
Shire Pharma Korea Yuhan Hoesa
|
Korea, Republic of
|
|
Shire Pharmaceutical Contracts Limited
|
United Kingdom
|
|
Shire Pharmaceutical Development Inc
|
United States
|
|
Shire Pharmaceutical Development Limited
|
United Kingdom
|
|
Shire Pharmaceutical Holdings Ireland Limited
|
Ireland
|
|
Shire Pharmaceutical Investment Trading Ireland
|
Ireland
|
|
Shire Pharmaceutical Investments 2008
|
Ireland
|
|
Shire Pharmaceuticals Group
|
United Kingdom
|
|
Shire Pharmaceuticals Iberica S.L.
|
Spain
|
|
Shire Pharmaceuticals International
|
Ireland
|
|
Shire Pharmaceuticals Investments (British Virgin Islands) Limited
|
Virgin Islands, British
|
|
Shire Pharmaceuticals Investments 2007
|
Ireland
|
|
Shire Pharmaceuticals Ireland Limited
|
Ireland
|
|
Shire Pharmaceuticals Limited
|
United Kingdom
|
|
Shire Pharmaceuticals LLC
|
United States
|
|
Shire Pharmaceuticals Mexico SA de CV
|
Mexico
|
|
Shire Pharmaceuticals Portugal, Lda
|
Portugal
|
|
Shire Pharmaceuticals Services Limited
|
United Kingdom
|
|
Shire Polska Sp. z o. o.
|
Poland
|
|
Shire Properties US
|
United States
|
|
Shire Regenerative Medicine LLC
|
United States
|
|
Shire Regulatory Inc
|
United States
|
|
Shire Rus Limited Liability Company
|
Russian Federation
|
|
Shire Singapore Pte. Ltd.
|
Singapore
|
|
Shire Supplies U.S. LLC
|
United States
|
|
Shire Sweden AB
|
Sweden
|
|
Shire Sweden Holdings S.a.r.l
|
Luxembourg
|
|
Shire UK Investments Limited
|
United Kingdom
|
|
Shire US Holdings LLC
|
United States
|
|
Shire US Inc
|
United States
|
|
Shire US Investment Inc
|
United States
|
|
Shire US Investments
|
United Kingdom
|
|
Shire US Manufacturing Inc
|
United States
|
|
Shire ViroPharma Incorporated
|
United States
|
|
Shire-Movetis NV
|
Belgium
|
|
Sparkleflame Limited
|
United Kingdom
|
|
Tanaud International BV
|
Netherlands
|
|
Tanaud Ireland Inc.
|
Ireland
|
|
The Endocrine Centre Limited
|
United Kingdom
|
|
VCO Incorporated
|
United States
|
|
ViroPharma AB
|
Sweden
|
|
Viropharma Biologics Inc
|
United States
|
|
Viropharma Canada Incorporated
|
Canada
|
|
Viropharma GmbH
|
Germany
|
|
Viropharma Holdings Limited
|
Bermuda
|
|
Viropharma Holdings LLC
|
United States
|
|
Viropharma Limited
|
United Kingdom
|
|
ViroPharma LLC
|
Switzerland
|
|
Viropharma Pty Ltd
|
Australia
|
|
Viropharma Puerto Rico Inc
|
Puerto Rico
|
|
Viropharma S.r.l
|
Italy
|
|
Viropharma SAS
|
France
|
|
Viropharma Spain SL
|
Spain
|
|
Viropharma SPRL
|
Belgium
|
|
Viropharma Sweden AB
|
Sweden
|
|
VPDE Incorporated
|
United States
|
|
VPINT Incorporated
|
United States
|
|
VPMP Incorporated
|
United States
|